Eplerenone clinical trials
Also written Inspra.
How each study uses Eplerenone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Eplerenone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Sept 2002 · INSPRA · NDA 021437 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
95 studies that test it; most in 2013 (13); 2 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 4 |
| 2004 | 4 |
| 2005 | 1 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 13 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 83
Brigham and Women's Hospital (10) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (6) · Central Hospital, Nancy, France (3) · Massachusetts General Hospital (3) · Radboud University Medical Center (3) · Hippocration General Hospital (2) · Vanderbilt University Medical Center (2) · Vanderbilt University (2)
Often tested with
Tested in the same studies.
Spironolactone (5) · Amlodipine (4) · Aliskiren (3) · Valsartan (2) · Ramipril (2) · Chlorthalidone (2) · Vicadrostat (1) · Fludrocortisone (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test Eplerenone.
- Nov 2026Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries (StratMed-MINOCA)Phase 2 · NHS National Waiting Times Centre Board
- Jan 2027Vascular Effects of High-Salt After PreeclampsiaEarly Phase 1 · Anna Stanhewicz, PhD
- Feb 2027Swedish Cardiac And Renal Failure Study-1Phase 2 · Karolinska Institutet
- Feb 2027Eplerenone and IOP in Healthy AdultsPhase 1 · University of Florida
- Feb 2027AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRPNot applicable · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Apr 2027Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in HypertensionPhase 4 · Brigham and Women's Hospital
- Oct 2027Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical StudyPhase 4 · Brigham and Women's Hospital
Studies
Open first, then newest update. How each study uses Eplerenone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 97
- AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRPNot yet recruitingNot applicableUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07933757Written as Eplerenone
- Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential HypertensionNot yet recruitingPhase 4China National Center for Cardiovascular DiseasesNCT07932145Written as Eplerenone
- Reducing Arterial Inflammation Using Eplerenone and Statins in HIVNot yet recruitingPhase 2/3Massachusetts General HospitalNCT07892664Written as Eplerenone
- Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of PregnancyRecruitingPhase 2Massachusetts General HospitalNCT07238400Written as Eplerenone 100 mg daily
- Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical StudyRecruitingPhase 4Brigham and Women's HospitalNCT05030545Written as Eplerenone
- Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation.Not yet recruitingPhase 3Central Hospital, Nancy, FranceNCT07828223Written as Eplerenone
- Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic StenosisNot yet recruitingPhase 2University College, LondonNCT07539259Written as Epleronone
- Eplerenone and IOP in Healthy AdultsNot yet recruitingPhase 1University of FloridaNCT07795762Written as Eplerenone
- Early Aldo Blockade in Subclinical PANot yet recruitingPhase 2/3Xinjiang Medical UniversityNCT07727252Written as Eplerenone
- Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in HypertensionRecruitingPhase 4Brigham and Women's HospitalNCT05593055Written as Eplerenone
- Swedish Cardiac And Renal Failure Study-1RecruitingPhase 2Karolinska InstitutetNCT07029503Written as Eplerenone
- Vascular Effects of High-Salt After PreeclampsiaRecruitingEarly Phase 1Anna Stanhewicz, PhDNCT06749418Written as Eplerenone
- Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical TreatmentRecruitingNot applicableGöteborg UniversityNCT05797558Written as Medical treatment (eplerenone)
- The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.RecruitingPhase 3Central Hospital, Nancy, FranceNCT04450953Written as Eplerenone 50mg/day (cross over design)
- Optimal Medical Treatment of Difficult-to-treat HypertensionRecruitingPhase 4National Institute of Cardiology, Warsaw, PolandNCT06275763Written as Phase C: Eplerenone
- The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.RecruitingNot applicableHippocration General HospitalNCT06208072Written as Eplerenone 25 mg
- Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart DiseaseNot yet recruitingPhase 4Assiut UniversityNCT06168994Written as Eplerenone
- A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart FailureEnrolling by invitationPhase 4Bispebjerg HospitalNCT03984591Written as Eplerenone
- Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries (StratMed-MINOCA)Active, not recruitingPhase 2NHS National Waiting Times Centre BoardNCT05198791Written as Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets
- MR and Inflammation After PreeclampsiaWithdrawnEarly Phase 1Anna Stanhewicz, PhDNCT07345845Written as Eplerenone
See all 97 studies that test Eplerenone →
Given beside what is tested · 2 — Eplerenone is usual care or a partner of the new treatment
- Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862CompletedPhase 1BayerNCT01473108Written as Eplerenone (Inspra®)
- A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male SubjectsCompletedPhase 1AstraZenecaNCT02532998Written as Eplerenone, tablets
As the comparator · 11 — what is tested is compared with Eplerenone
- Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy SubjectsCompletedPhase 1Santhera PharmaceuticalsNCT06649409Written as Eplerenone
- Bioequivalence Study of Test and Reference 50 mg Eplerenone Film-coated Tablets in Healthy VolunteersCompletedPhase 1Darnitsa Pharmaceutical CompanyNCT05663372Written as INSPRA® 50 mg eplerenone film-coated tablets
- Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease AloneCompletedPhase 2BayerNCT01955694Written as Eplerenone
- A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential HypertensionCompletedPhase 2Novartis PharmaceuticalsNCT00758524Written as Eplerenone
- Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease AloneCompletedPhase 2BayerNCT01807221Written as Inspra (eplerenone)
- A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant HypertensionCompletedPhase 2NovartisNCT00817635Written as Eplerenone
- LFF269 Compared to Placebo After Treatment in Subjects With Essential HypertensionTerminatedPhase 2Novartis PharmaceuticalsNCT01373086Written as Eplerenone
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive SubjectsCompletedPhase 2Daiichi SankyoNCT02345044Written as eplerenone
- A Study of LY2623091 in Male and Females With Chronic Kidney DiseaseCompletedPhase 2Eli Lilly and CompanyNCT01427972Written as Eplerenone
- Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium ClearanceCompletedPhase 1Eli Lilly and CompanyNCT01237899Written as Eplerenone
- Study of CS-3150 in Patients With Essential HypertensionCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02890173Written as Eplerenone
What changed recently
From the registry's own updates since Oct 20, 2026.
Stopped1
- MR and Inflammation After PreeclampsiaWithdrawnOct 29, 2026NCT07345845
Newly registered3
- Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential HypertensionNov 12, 2026NCT07932145
- AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRPNov 12, 2026NCT07933757
- Reducing Arterial Inflammation Using Eplerenone and Statins in HIVOct 23, 2026NCT07892664
Codes
What other systems call Eplerenone · ClinicalTrials.gg INT006742
- MeSH (NLM) D000077545EplerenoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6995V82D0BEPLERENONEConfirmed FDA, NLM, Wikidata
- RxNorm 298869Confirmed FDA, Wikidata
- Wikidata Q423804eplerenoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47513EplerenoneConfirmed FDA, Wikidata
- DrugBank DB00700One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077545 | Eplerenone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6995V82D0B | EPLERENONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 298869 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423804 | eplerenone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47513 | Eplerenone | Confirmed FDA, Wikidata |
| DrugBank | DB00700 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.